Introduction
Although marked as an "orphan disease" in developed countries, bronchiectasis is not uncommon in developing countries with significant morbidity and mortality [1] . The underlying mechanism can be detected in only 40% of patients [2] and only a minority of patients benefit from specific treatment. The common symptoms of patients with bronchiectasis are cough with sputum and dyspnoea. The former symptoms are usually well controlled with antibiotics and postural drainage. Dyspnoea varies in severity and is often associated with wheezing, which may simulate asthma [3] . Some authors suggest that atopy is genetically an intrinsic part of bronchiectasis, while others propose that it is a consequence of prolonged, excessive stimulation of the immune system by chronic infection. Bronchiectasis, a condition where pulmonary pathological changes are in many respects similar to those of cystic fibrosis, is lacking also in literature investigating its relation to atopy [4] .
Although an increased prevalence of airway obstruction, bronchial hyperreactivity and allergic diseases such as asthma has been associated with bronchiectasis [5] , studies investigating role of atopy in bronchiectasis are few and controversial. We have therefore studied IgE level and reversible airways obstruction in bronchiectasis and its relation to pulmonary function tests, which have not previously been evaluated in bronchiectasis.
Patients and Methods
This study was conducted at Department of chest diseases of Al-Azhar University, Assuit, Egypt from January 2012 to December 2013. All consecutive patients with bronchiectasis admitted to the department were enrolled to the study. Patients with any known cause of bronchiectasis including established diagnosis of asthma and allergic bronchopulmonary aspergillosis, previous tuberculosis, autoimmune and collagen-vascular diseases were excluded. Finally 50 patients with bronchiectasis without any known etiology were included. Patients' characteristics including age, sex, smoking history, disease duration, history of familial atopy, childhood and current allergic disease were recorded.
Patients were divided into two groups of 32 (study group) and 18 patients (controls) respectively according to IgE level (raised total serum IgE of greater than 200 IU/ml) [6] . No patients had evidence of colonization with A fumigatus, either from sputum culture, specific IgE or precipitin tests. Eighteen bronchiectasis subjects who had normal IgE served as controls. All subjects answered a respiratory questionnaire, documenting family history of chest disease, smoking habits, and current symptoms such as cough, sputum quality and volume, haemoptysis, and dyspnoea. Additionally, duration of symptoms, precipitating illness, concurrent or past illness, and current treatment were recorded. Each subject completed an atopy questionnaire, recording personal or family history of asthma, wheeze, eczema, urticaria, allergic rhinitis, angioneurotic oedema, contact dermatitis, and drug allergy. An informed consent was obtained from all study subjects. The study was approved by the local ethics committee of Al-Azhar University. Serum IgE was measured by radioimmunoassay. Blood eosinophil count was measured by the counting chamber method [7] .
Diagnostic Criteria and HRCT Scoring
In all patients, HRCT scans with 1 mm collimation at 10 mm intervals were obtained through the thorax at end inspiration and they were interpreted by two radiologists who were blinded to clinical history and chest x-ray findings. Criteria for the diagnosis of bronchiectasis utilizing HRCT included the following: 1) dilatation of bronchi as determined by an increased bronchial/adjacent pulmonary artery ratio (ratio > 1) when imaged in cross section (signet-ring sign), 2) parallel bronchial walls when seen in longitudinal section (tram sign), and 3) demonstration of bronchi in the peripheral third of the lung [8] . Bronchiectasis was scored as previously described using the modified Bhalla scoring system [9] . This score has been validated in adult and pediatric patients with bronchiectasis and assigns a value to each lobe and the lingula as follows: bronchiectasis extent (0 -3), bronchial wall dilatation (0 -3) and thickness (0 -3), presence of mucus in large (0 -1) and small airways (0 -1), air trapping (0 -4), atelectasis (0 -1) and consolidation (0 -1) resulting in a worst possible score of 16. The higher HRCT score represented the more extended and severe bronchiectasis.
Spirometry
Lung function measurements were performed using a spirometer (Sensormedics, Germany) according to the standardized procedures of the European Respiratory Society [10] . Volume calibration of the spirometer was done before each measurement. The forced vital capacity (FVC) and forced expiratory volume in one second (FEV 1 ) were taken as the highest readings obtained from at least three satisfactory forced expiratory maneuvers. The participants' baseline lung function was compared with the reference values and expressed as percent of the predicted values.
Statistical Analysis
SPSS (SPSS for Windows, SPSS Inc., Chicago, IL, USA) statistical package were used for statistical analyses. Descriptive statistics were shown as mean ± S.D. Univariate analysis was performed using chi-square test for proportion of atopy, sex differences in the study and control groups. To compare parametric values of the groups including age, disease duration, mean HRCT and atopy scores and lung function parameters, Student's t-test was used. Correlation of the atopy score with lung function parameters and HRCT score was investigated by Pearson correlation test. A p value less than 0.05 was considered statistically significant.
Results
Demographic characteristics of both groups did not show a significant difference ( Table 1) . Smoking habit did not differ significantly between them. The main symptoms were chronic productive cough, which was present in all patients; dyspnoea on exertion, present in 23 (46%); and haemoptysis, which was reported in 8 (16%). Lung auscultation identified crepitations in 16 patients (32%) and 19 (38%) had finger clubbing. High IgE level was found in 32 of our patients (64%), whereas 18 patients had normal level (36%). There were significant differences between the groups in in mean serum IgE concentrations (264 U/ml; versus 47 U/ml). High IgE patients had longer disease duration, frequent history of familial atopy, childhood and current allergic disease than controls ( Table 2) . They had also significantly worse FEV 1 (49.38 ± 12.65; p = 0.041) and FEV 1 /FVC (60.89 ± 13.52; p = 0.015) values. The extent of the disease on HRCT varied from a single lobe affected in four patients in control group to all lobes in 15 patients in study group. Mean HRCT score was significantly higher in the study group (23.6 ± 10.1) than in controls (7.83 ± 2.43) ( Table 3) . HRCT scores and IgE values (Figure 1) negatively correlated with FEV 1 and FEV 1 /FVC ( Table 4) . IgE showed positive correlation (r = 0.266, p = 0.015) with HRCT scores (Figure 2) . Furthermore, the mean increase in FEV I after inhalation of salbutamol was significantly greater (p = 0.002) in the study patients than in controls. Similarly, the mean FEV 1 /FVC was lower and showed a significantly greater (p = 0.009) improvement after inhalation of salbutamol. Finally, the FVC showed significantly greater (p = 0.007) improvement in those with high IgE level (study group).
Discussion
Bronchiectasis is a disease that no cause can be defined in about 40% of the cases [11] . It is characterized generally by bronchial obstruction and hyperreactivity of which the mechanisms, however, are not well understood [12] [13] . It has been suggested that mucosal edema, glandular hyperplasia and excessive airway collapse in expiration might result in bronchial obstruction [14] . Association of atopy and allergic diseases such as asthma and alteration of bronchial smooth muscle and autonomic neural regulation due to increased access to toxins through infected or inflamed bronchial mucosa could cause bronchial hyperreactivity [15] . The reported prevalence of atopy in patients with bronchiectasis varies from 30% to 42% [16] . The application of wider diagnostic criteria probably explains the higher prevalence of atopy (64%) in our patients. This study has also demonstrated that atopic patients with bronchiectasis had significantly worse pulmonary functions and higher HRCT score, than non-atopic bronchiectasis. Furthermore IgE was correlated positively with HRCT score and negatively with pulmonary function parameters of FEV 1 and FEV 1 /FVC. These findings indicate that the more severe atopy results in the worse pulmonary function and the more extended and severe bronchiectasis. According to our results, atopy may have a role in bronchial obstruction in bronchiectasis. One may have thought that our results are in conflict with hygiene hypothesis with regard to development of atopy and allergic diseases since recurrent respiratory infections in bronchiectasis would give rise to expect a decreased prevalence of atopy [17] . Some infections that may be associated with both atopy and bronchiectasis such as allergic bronchopulmonary aspergillosis and pertussis [18] . Paunio et al. [19] reported that measles and atopy had occurred more frequently together than expected. Furthermore Bager et al. [17] reported that Danish women with measles during the first year of life were associated with a 3.4-fold increase in the odds ratio of atopy. Other investigations revealed there was no relationship between them due to the biphasic response of natural measles infection [20] [21] . Staphylococcus infection, which is a significant cause of bronchiectasis [22] [23] can be associated with atopy through IL-5 stimulation. The association of bronchiectasis and hepatitis B virus infection that can induce atopy may be another explanation of association of bronchiectasis and atopy [24] due to Th-2 response [25] [26] . High incidence of comorbidity with bacterial infections including sinusitis [27] in atopic subjects may be a contributing factor in pathogenesis of bronchiectasis, suggesting that it might have resulted in higher probability of bronchiectasis [28] . Another study revealed that elevated concentrations of serum amyloid-A in patients with allergic airway disease might reflect presence of a systemic inflammation [29] . We suppose that atopy may be a causative, as well as a coincidence, furthermore atopy might be deteriorating factor for bronchiectasis since IgE level has been positively correlated with HRCT score, in other words, the more atopy is the more extended bronchiectasis will be. The results of the studies in the literature investigating the prevalence of atopy in bronchiectasis are few in number and conflicting [30] . Varpela et al. [31] found prevalence of atopy in their series of 48 patients with bronchiectasis was 10%. Their study was uncontrolled and diagnosis of bronchiectasis was based on bronchography, which is less sensitive than HRCT used in our study. In another study of Hassan et al. [32] , atopy was found in 13 of 24 (54%) patients with bronchiectasis while Pang et al. [13] and Murphy et al. [28] reported atopy prevalence as 25% and 30%, respectively. The different results of other studies could be attributed to methodological differences. Although findings of Hassan et al. [32] were similar to our results, their study was uncontrolled. Our study population was larger and significant correlations of atopy score with HRCT score and lung function tests have been reported.
We have shown a significant reversibility of airway obstruction after inhalation of salbutamol in atopic patients with bronchiectasis. Previous studies on bronchodilators in bronchiectasis have been infrequent and old.
Cherniak and Carton [33] showed negligible changes in FEV 1 , FVC, or RV after inhalation of bronchodilators, while others [34] showed no significant change in inspiratory or expiratory pulmonary resistance or dynamic compliance. According to our results we would suggest that all patients with bronchiectasis should have an assessment of the reversibility of airways obstruction by beta adrenergic agonists, before its addition in treatment.
In conclusion, atopy is significantly frequent in bronchiectasis and it may lead to worse pulmonary function and more HRCT extent. Clinicians should be aware of this issue, however exact relationship with these entities, remains to be investigated by means of other larger sample size studies.
